Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2016

Open Access 01-12-2016 | Research

SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males

Authors: Zhisen Shen, Xiaoying Chen, Qun Li, Chongchang Zhou, Jinyun Li, Huadan Ye, Shiwei Duan

Published in: Diagnostic Pathology | Issue 1/2016

Login to get access

Abstract

Background

Somatostatin receptor 2 (SSTR2) encodes somatostatin receptor that can inhibit the cell proliferation of solid tumors. Promoter hypermethylation is likely to silence the expression of SSTR2. The goal of our study was to investigate the association between SSTR2 promoter methylation and the risk and progression of laryngeal carcinoma.

Methods

In the current study, tumor tissues and their adjacent non-tumor tissues were collected from a total of 87 laryngeal squamous cell carcinoma (LSCC) male patients. DNA methylation levels of nine SSTR2 promoter CpGs were measured using the bisulphite pyrosequencing technology.

Results

Our results revealed that there was a significantly increased SSTR2 promoter methylation in LSCC tissues than in their adjacent non-cancerous tissues (adjusted P = 0.003). Breakdown analysis by age indicated that the significant association was mainly contributed by patients younger than 60 (adjusted P = 0.039) but not in patients older than 60. Meanwhile, the significant association was observed in the patients with moderately (adjusted P = 0.037) and well differentiated tissues (adjusted P = 0.028), as well as the patients with histological stage IV (adjusted P = 0.031). Multivariate Cox analysis suggested that SSTR2 promoter methylation was an independent prognostic factor of LSCC (HR = 1.127, 95 % CI = 1.034–1.228).

Conclusions

In conclusion, SSTR2 promoter hypermethylation might be associated with the risk and progression of LSCC in males.
Literature
1.
Morshed K, Polz-Dacewicz M, Szymanski M, Polz D. Short-fragment PCR assay for highly sensitive broad-spectrum detection of human papillomaviruses in laryngeal squamous cell carcinoma and normal mucosa: clinico-pathological evaluation. Eur Arch Otorhinolaryngol. 2008;265 Suppl 1:S89–96.CrossRefPubMed
2.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6.CrossRefPubMed
3.
Rudolph E, Dyckhoff G, Becher H, Dietz A, Ramroth H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. Eur Arch Otorhinolaryngol. 2011;268:165–79.CrossRefPubMed
4.
Kada S, Hirano S, Tateya I, Kitamura M, Ishikawa S, Kanda T, et al. Ten years single institutional experience of treatment for advanced laryngeal cancer in Kyoto University. Acta Otolaryngol Suppl. 2010:68–73
5.
Toporcov TN, Znaor A, Zhang ZF, Yu GP, Winn DM, Wei Q, et al. Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. Int J Epidemiol. 2015;44:169–85.CrossRefPubMed
6.
Yang M, Li W, Liu YY, Fu S, Qiu GB, Sun KL, et al. Promoter hypermethylation-induced transcriptional down-regulation of the gene MYCT1 in laryngeal squamous cell carcinoma. BMC Cancer. 2012;12:219.PubMedCentralCrossRefPubMed
7.
Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. J Endocrinol Invest. 2005;28:5–9.PubMed
8.
Goel A. Somatostatin methylation as a biomarker for gastric cancer: ready for “prime time” or for further validation? Dig Dis Sci. 2011;56:1–3.CrossRefPubMed
9.
Misawa K, Misawa Y, Kondo H, Mochizuki D, Imai A, Fukushima H, et al. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma. PLoS One. 2015;10, e0118588.PubMedCentralCrossRefPubMed
10.
Liu Z, Marquez M, Nilsson S, Holmberg AR. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep. 2008;20:151–4.PubMed
11.
Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll AM, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995;92:1580–4.PubMedCentralCrossRefPubMed
12.
Condon LT, Stafford ND, Bedford KJ, MacDonald AW, Atkin SL. The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. Eur Arch Otorhinolaryngol. 2008;265 Suppl 1:S63–7.CrossRefPubMed
13.
Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, et al. Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology. 2008;149:3137–47.CrossRefPubMed
14.
Xiaoying C, Huadan Y, Qingxiao H, Annan Z, Linlin T, Shiwei D. The effects of DNA methylation on the homeostasis in vascular diseases. Yi Chuan. 2015;37:221–32.PubMed
15.
Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li Y, et al. The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. PLoS One. 2014;9, e96822.PubMedCentralCrossRefPubMed
16.
Huang T, Chen X, Hong Q, Deng Z, Ma H, Xin Y, et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Sci Rep. 2015;5:8897.PubMedCentralCrossRefPubMed
17.
Jiang D, Shen Y, Dai D, Xu Y, Xu C, Zhu H, et al. Meta-analyses of methylation markers for prostate cancer. Tumour Biol. 2014;35:10449–55.CrossRefPubMed
18.
Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F, et al. Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol. 2013;8:199.PubMedCentralCrossRefPubMed
19.
Li Z, Ding S, Zhong Q, Li G, Zhang Y, Huang XC. Significance of MMP11 and P14(ARF) expressions in clinical outcomes of patients with laryngeal cancer. Int J Clin Exp Med. 2015;8:15581–90.PubMedCentralPubMed
20.
Williamson JS, Harris DA, Beynon J, Jenkins GJ. Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer. Clin Epigenetics. 2015;7:70.PubMedCentralCrossRefPubMed
21.
Xu L, Zheng D, Wang L, Jiang D, Liu H, Xu L, et al. GCK gene-body hypomethylation is associated with the risk of coronary heart disease. Biomed Res Int. 2014;2014:151723.PubMedCentralPubMed
22.
Zhang Y. Zhang J. Mol Biosyst: Identification of functionally methylated regions based on discriminant analysis through integrating methylation and gene expression data; 2015.
23.
Chen AY, Fedewa S, Zhu J. Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985–2007. Arch Otolaryngol Head Neck Surg. 2011;137:1017–24.CrossRefPubMed
24.
Liu Y. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions. Cancer Lett. 2006;239:21–6.CrossRefPubMed
25.
Wang J, Chen H, Fu S, Xu ZM, Sun KL, Fu WN. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral Oncol. 2011;47:601–8.CrossRefPubMed
26.
He L, Ji W, Yang J, Zhao X. Study of mRNA expression level and hypermethylation of CHFR promoter in the laryngeal squamous cell carcinoma tissue. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24:673–7.PubMed
27.
Bai W, Li W, Chen X, Wang T. The relationship between hypermethylation of the PTEN promoter and laryngeal squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006;20:254–6.PubMed
28.
Yin D, Dong M. Methylation of promoter and expression of FHIT gene in laryngeal squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005;19:253–5. 8.PubMed
29.
Lopez F, Sampedro T, Llorente JL, Dominguez F, Hermsen M, Suarez C, et al. Utility of MS-MLPA in DNA methylation profiling in primary laryngeal squamous cell carcinoma. Oral Oncol. 2014;50:291–7.CrossRefPubMed
30.
Ren G, Zhao DA, Xu J, Li BA. Expression of CBY and methylation of CBY at promoter region in human laryngeal squamous cell carcinoma. Tumori. 2015;101:215–22.CrossRefPubMed
31.
Hu J, Zhao R, Wu G, Wang J. Expression and methylation status of IGFBP-rP1 gene in laryngocarcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013;27:1352–4. 9.PubMed
32.
Stafford ND, Condon LT, Rogers MJ, MacDonald AW, Atkin SL. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clin Otolaryngol Allied Sci. 2003;28:314–9.CrossRefPubMed
33.
Chen K, Song F, He M, Li H, Qian B, Zhang W, et al. Trends in head and neck cancer incidence in Tianjin, China, between 1981 and 2002. Head Neck. 2009;31:175–82.CrossRefPubMed
34.
Sakai K, Yonezawa T, Yamawaki H, Oyamada T. Alteration of somatostatin receptor 2 expression in canine mammary gland tumor. J Vet Med Sci. 2015;77:1319–22.PubMedCentralCrossRefPubMed
35.
Hennigs JK, Muller J, Adam M, Spin JM, Riedel E, Graefen M, et al. Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse. PLoS One. 2014;9, e100469.PubMedCentralCrossRefPubMed
36.
Shi WD, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Liu LM. Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett. 2009;283:84–91.CrossRefPubMed
37.
Vasilenko Iu S, Pavlikhin OG, Izgarysheva ZA. Analysis of the causes of vocal tract diseases in singers. Vestn Otorinolaringol. 2000:13–7.
Metadata
Title
SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males
Authors
Zhisen Shen
Xiaoying Chen
Qun Li
Chongchang Zhou
Jinyun Li
Huadan Ye
Shiwei Duan
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2016
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-016-0461-y

Other articles of this Issue 1/2016

Diagnostic Pathology 1/2016 Go to the issue

Case Report

Glioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: a case report

Case Report

Maxillary calcifying epithelial odontogenic tumor with sinus and buccal vestibule extension: a case report and immunohistochemical study

Case Report

Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma

Research

Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis

Research

Frequent detection of human polyomavirus 6 in keratoacanthomas

Research

TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma